Genetic Passive Immunization with Adenoviral Vector Expressing Chimeric Nanobody-Fc Molecules as Therapy for Genital Infection Caused by Mycoplasma hominis

Burmistrova, D.A.; Tillib, S.V.; Shcheblyakov, D.V.; Dolzhikova, I.V.; Shcherbinin, D.N.; Zubkova, O.V.; Ivanova, T.I.; Tukhvatulin, A.I.; Shmarov, M.M.; Logunov, D.Y.

Статья опубликована в высокорейтинговом журнале

Информация о цитировании статьи получена из Web of Science, Scopus
Статья опубликована в журнале из списка Web of Science и/или Scopus
Дата последнего поиска статьи во внешних источниках: 10 мая 2016 г.

Авторы: Burmistrova Daria A., Tillib Sergey V., Shcheblyakov Dmitry V., Dolzhikova Inna V., Shcherbinin Dmitry N., Zubkova Olga V., Ivanova Tatiana I., Tukhvatulin Amir I., Shmarov Maxim M., Logunov Denis Y.
Журнал: PLoS ONE
Том: 11
Номер: 3
Год издания: 2016
Издательство: Public Library of Science
Местоположение издательства: United States
Первая страница: e0150958
DOI: 10.1371/journal.pone.0150958
Аннотация: Developing pathogen-specific recombinant antibody fragments (especially nanobodies) is a very promising strategy for the treatment of infectious disease. Nanobodies have great potential for gene therapy application due to their single-gene nature. Historically, Mycoplasma hominis has not been considered pathogenic bacteria due to the lack of acute infection and partially due to multiple studies demonstrating high frequency of isolation of M. hominis samples from asymptomatic patients. However, recent studies on the role of latent M. hominis infection in oncologic transformation, especially prostate cancer, and reports that M. hominis infects Trichomonas and confers antibiotic resistance to Trichomonas, have generated new interest in this field. In the present study we have generated specific nanobody against M. hominis (aMh), for which the identified target is the ABC-transporter substrate-binding protein. aMh exhibits specific antibacterial action against M. hominis. In an attempt to improve the therapeutic properties, we have developed the adenoviral vector-based gene therapy approach for passive immunization with nanobodies against M. hominis. For better penetration into the mucous layer of the genital tract, we fused aMh with the Fc-fragment of IgG. Application of this comprehensive approach with a single systemic administration of recombinant adenovirus expressing aMh-Fc demonstrated both prophylactic and therapeutic effects in a mouse model of genital M. hominis infection.
Добавил в систему: Должикова Инна Вадимовна

	ИСТИНА	Войти в систему Регистрация
	ИСТИНА ЦЭМИ РАН
	Главная Поиск Статистика О проекте Помощь

ИСТИНА

ИСТИНА ЦЭМИ РАН

Genetic Passive Immunization with Adenoviral Vector Expressing Chimeric Nanobody-Fc Molecules as Therapy for Genital Infection Caused by Mycoplasma hominisстатья

Прикрепленные файлы